Total
0
Shares
UCW (ASX:UCW) doubles down on unsolicited RedHill Education (ASX:RDH) takeover bid
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • CannPal Animal Therapeutics (CP1) shares have ceased trading on the ASX at the close of today's session after they were acquired by AusCann Group (AC8)
  • The Court orders approving the scheme of arrangement were lodged with the Australian Securities and Investments Commission today, making the scheme legally effective
  • Shareholders in the animal health company will receive 1.3 new AusCann shares for every CannPal share held on the record date of March 15, 2021
  • Those new shares will be transferred on March 18, 2021
  • CannPal shares last traded at 17 cents, while AusCann Group closed flat at 14.5 cents

CannPal Animal Therapeutics (CP1) shares have ceased trading on the ASX at the close of today's session after they were acquired by AusCann Group (AC8).

AusCann is an Australian pharmaceutical company and entered a scheme implementation deed in November 2020 to acquire all CannPal shares.

Under the terms of the scheme, CannPal shareholders were offered 1.3 AusCann shares, valuing CannPal shares at 18.4 cents each and the animal health company at $17.5 million on a fully-diluted basis.

The court orders approving the scheme of arrangement were lodged with the Australian Securities and Investments Commission today, making the scheme legally effective.

CannPal shareholders will receive 1.3 new AusCann shares for every CannPal share held on the record date of March 15, 2021.

Those new shares will be transferred when the Scheme is implemented on March 18, 2021.

Speaking on the rationale for the acquisition in November, AusCann Chairperson Max Johnston said the synergies it would create would accelerate growth within the burgeoning sector.

"The combined business is expected to have the financial resources and technical expertise to accelerate the growth, commercialisation and market penetration of its pipeline products in Australia and offshore."

"The complementary nature of developing new health solutions for both human and animal and creating a much larger addressable market makes this combination a game-changer for both companies."

"The combined resources position the new company well to take a leadership position within this new health industry sector," he concluded.

CannPal shares last traded at 17 cents, while AusCann Group closed flat at 14.5 cents.

CP1 by the numbers
More From The Market Herald
Imricor Medical Systems (ASX:IMR) - Chair and CEO, Steve Wedan - The Market Herald

" Imricor Medical Systems (ASX:IMR) signs agreement with MiRTLE Medical

Imricor Medical Systems (IMR) has signed an agreement with MiRTLE Medical for its 12-lead ECG system.
Telix Pharmaceuticals (ASX:TLX) - CFO, Doug Cubbin - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) bags $12.1m R&D tax refund, increases overseas finding to $139m

Telix Pharmaceuticals (TLX) has pocketed a research and development (R&D) tax refund of $12.1 million for eligible activities undertaken in the 2020 calenda…
Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron - The Market Herald

" Mach7 (ASX:M7T) provides PACS Solution to Trinity Health in US

Mach7 Technologies (M7T) has received purchase orders for its software and services from Trinity Health totalling $3.6 million.
Pfizer tests new antiviral pill

" Pfizer tests new antiviral pill

Major vaccine producer Pfizer says it will start trials for an antiviral pill for those who have been exposed to COVID-19.